On average, from discovery to market, drug development takes 10 to 15 years and costs almost $3 billion. Furthermore, despite all invested time and effort, up to 9 out of 10 drug candidates fail in clinical trials. Pharma companies have been exploring technology-based solutions and partnerships to help them identify new drug targets accelerating drug discovery and design. 

Harnessing artificial intelligence (AI) and machine learning (ML) may save time and resources at every step of the innovation cycle, ultimately resulting in a stronger operating model. However, there are challenges: how will this new model be adapted seamlessly by traditional pharmaceutical companies? How does digitalisation affect different parts of the pharma value chain? How do pharma companies judge the value of investing in AI/ML to support drug discovery and development? 

This webinar discussion, hosted by the Financial Times and BIOVIA, Dassault Systèmes, will explore how adapting AI and ML can revolutionise early stage drug development. There will also be discussions around how pharma and software companies can work together to generate success on both sides.

Understand

The big picture, not just the individual strands of the business you work in

Connect

And build relationships with some of the biggest names in your industry

Discover

New approaches and strategies to help win market share

Premier Digital Events Supported by the World's Best Journalism

Using leading digital technology, we have now taken our content, global audience reach and engagement to a new level through a series of unmissable virtual events. Our compelling events are chaired by respected FT journalists, feature the most senior and thought-provoking decision-makers in business, finance and politics, all accessible from your office or home.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice